HCPCS Code J9177: Injection, Enfortumab Vedotin-Ejfv, 0.25 mg

## **J9177 documentation requirements** Accurate, comprehensive documentation supports correct unit billing and payer compliance. ### **Diagnosis and prior therapy** Record the cancer type (e.g., malignant neoplasm of urinary bladder), the primary carcinoma site, and clinical status (e.g., metastatic urothelial cancer). Include prior PD-1/L1 therapy and exposure or ineligibility for cisplatin containing chemotherapy, noting subsequent therapy use for persistent disease or metastatic disease progression. ### **Dose and units** Document total milligrams administered and corresponding J9177 units (0.25 mg per unit). Weight, body surface area (if used), and calculation steps should be included. ### **Route, timing, and technique** Record IV route, start/stop times, and the intravenous infusion technique used (initial hour and any additional time). ### **Drug identification** Capture brand/generic, strength, dose size, lot number, expiration date, and NDC to support the claim. ### **Monitoring and adverse events** Document vitals, labs (e.g., glucose, renal), skin and neuropathy checks, and any ocular disorders or infusion reactions observed. ### **Guidelines and medical necessity** Note alignment with national comprehensive cancer network recommendations when applicable and include the oncologist’s rationale for regimen selection.

## **J9177 billing requirements** Follow these guidelines to ensure accurate reimbursement for J9177. ### **Correct unit reporting** Bill per 0.25 mg unit; total units must precisely match the administered dose (no rounding). ### **Modifiers for wastage** Report drug actually administered on one line. If wastage from a single-dose vial occurs, bill the discarded amount on a second line with JW; use JZ when no drug was discarded. ### **CPT pairing for administration** Pair with appropriate chemotherapy administration codes reflecting the intravenous infusion technique (see “Other relevant codes”). ### **NDC and claim accuracy** Include the correct NDC on Medicare Part B claims and ensure units, dates, and site of care are consistent across the claim and chart. ### **Authorization and coverage** Check payer policies (including medicare and commercial) for prior authorization, frequency limits, and site-of-service rules; confirm whether services are covered.

## **J9177 applicable modifiers** Use modifiers to indicate wastage status and satisfy payer rules. - **JW - Drug amount discarded/not administered:** Append to the line representing the wasted portion from a single-dose vial when documented discard occurs. - **JZ - Zero drug wasted:** Append when the entire single-dose vial was used with no discard (required on Medicare claims since July 1, 2023). - **99 - Multiple modifiers (when needed):** Use if payer policy requires multiple modifier reporting on the same line. - **UD / U7 / SB (payer-specific):** May be allowable per plan rules (e.g., program identifiers or specialized benefits). Verify with the payer before use.

## **Other relevant codes** The following CPT chemotherapy administration codes commonly appear with J9177; choose based on how the drug was delivered and session details: - **96413:** Chemotherapy administration, intravenous infusion technique; first hour, single or initial substance/drug. - **96415:** Each additional hour of chemotherapy IV infusion (list separately in addition to code for primary procedure). - **96417:** Each additional sequential chemotherapy infusion of a different drug, up to 1 hour. - **96409:** Chemotherapy administration, IV push, single or initial substance/drug. - **96375:** Each additional sequential IV push of a new substance/drug (when applicable per payer rules).